Your browser doesn't support javascript.
loading
Epithelial-to-mesenchymal transition (EMT) to sarcoma in recurrent lung adenosquamous carcinoma following adjuvant chemotherapy.
Poh, Mau Ern; Liam, Chong Kin; Mun, Kein Seong; Chai, Chee Shee; Wong, Chee Kuan; Tan, Jiunn Liang; Loh, Thian Chee; Chin, Ka Kiat.
Afiliación
  • Poh ME; Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  • Liam CK; Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  • Mun KS; Department of Pathology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  • Chai CS; Department of Medicine, Faculty of Medicine, University Malaysia Sarawak, Sarawak, Malaysia.
  • Wong CK; Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  • Tan JL; Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  • Loh TC; Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  • Chin KK; Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Thorac Cancer ; 10(9): 1841-1845, 2019 09.
Article en En | MEDLINE | ID: mdl-31350945
ABSTRACT
Adjuvant chemotherapy has long been indicated to extend survival in completely resected stage IB to IIIA non-small cell lung cancer (NSCLC). However, there is accumulating evidence that chemotherapy or chemoradiotherapy can induce epithelial-to-mesenchymal transition (EMT) in disseminated or circulating NSCLC cells. Here, we describe the first case of EMT as the cause of recurrence and metastasis in a patient with resected stage IIB lung adenosquamous carcinoma after adjuvant chemotherapy. We review the literature and explore the possible mechanisms by which EMT occurs in disseminated tumor cells (DTC) or circulating tumor cells (CTC) in response to adjuvant chemotherapy (cisplatin) as a stressor. We also explore the possible therapeutic strategies to reverse EMT in patients with recurrence. In summary, although adjuvant cisplatin-based chemotherapy in resected NSCLC does extend survival, it may lead to the adverse phenomenon of EMT in disseminated tumor cells (DTC) or circulating tumor cells (CTC) causing recurrence and metastasis.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sarcoma / Protocolos de Quimioterapia Combinada Antineoplásica / Quimioterapia Adyuvante / Carcinoma Adenoescamoso / Transición Epitelial-Mesenquimal / Neoplasias Pulmonares / Recurrencia Local de Neoplasia Tipo de estudio: Prognostic_studies Límite: Aged / Humans / Male Idioma: En Revista: Thorac Cancer Año: 2019 Tipo del documento: Article País de afiliación: Malasia Pais de publicación: SG / SINGAPORE / SINGAPUR / SINGAPURA

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sarcoma / Protocolos de Quimioterapia Combinada Antineoplásica / Quimioterapia Adyuvante / Carcinoma Adenoescamoso / Transición Epitelial-Mesenquimal / Neoplasias Pulmonares / Recurrencia Local de Neoplasia Tipo de estudio: Prognostic_studies Límite: Aged / Humans / Male Idioma: En Revista: Thorac Cancer Año: 2019 Tipo del documento: Article País de afiliación: Malasia Pais de publicación: SG / SINGAPORE / SINGAPUR / SINGAPURA